Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy

Launched by PENG LIANG · Nov 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two muscle relaxants, mivacurium chloride and succinylcholine, to see which one helps patients relax their muscles better during a bronchoscopy, a procedure where doctors look inside the lungs. The main goal is to find out if patients can start breathing on their own within 15 minutes after using mivacurium chloride, and whether it works as well as succinylcholine in terms of comfort and safety during and after the procedure.

To participate in this trial, you need to be an adult aged 18 to 60 who is scheduled for a bronchoscopy and requires muscle relaxation during anesthesia. You should also be in good overall health, without serious medical conditions that could complicate the procedure. If you join the study, you will receive either mivacurium chloride or succinylcholine during the bronchoscopy, and your vital signs will be closely monitored. After the procedure, the doctors will check how quickly you recover and how comfortable you feel. It’s important to note that this trial is not yet recruiting, so you would need to wait for it to start if you're interested.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients scheduled for painless bronchoscopy who require muscle relaxants during anesthesia.
• • 2. Aged between 18 and 60 years.
• • 3. Classified as Grade I-III according to the American Society of Anesthesiologists (ASA) Physical Status Classification.
• • 4. Patients voluntarily participate and sign an informed consent form.
• Exclusion Criteria:
• • 1. Patients with known allergies to any of the drugs involved in the study.
• • 2. Patients with severe organic diseases of the brain, heart, lungs, liver, kidneys, or other major organs.
• • 3. Patients with intracranial hypertension, asthma, cataracts, glaucoma, or other eye diseases.
• • 4. Patients with myasthenia gravis, myasthenic syndrome, severe reduction or deficiency of cholinesterase, upper motor neuron injury, or upper motor neuron diseases that may cause abnormal responses to muscle relaxants.
• • 5. Patients who have used medications affecting neuromuscular transmission function before the procedure.
• • 6. Pregnant or breastfeeding patients.
• • 7. Patients who have experienced extensive burns, acid-base imbalance, or electrolyte disturbances within the past six months.
• • 8. Patients known or suspected to be homozygous for the atypical gene for plasma cholinesterase.